Ligand Pharmaceuticals (LGND) – Research Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of Ligand Pharmaceuticals (NASDAQ: LGND) recently:

• 7/21/2026 – Ligand Pharmaceuticals is now covered by Citigroup Inc.. They set a “buy” rating and a $387.00 price target on the stock.
• 7/15/2026 – Ligand Pharmaceuticals had its price target raised by Royal Bank Of Canada from $262.00 to $340.00. They now have an “outperform” rating on the stock.
• 7/9/2026 – Ligand Pharmaceuticals had its price target raised by Bank of America Corporation from $266.00 to $388.00. They now have a “buy” rating on the stock.
• 7/8/2026 – Ligand Pharmaceuticals had its price target raised by Stifel Nicolaus from $255.00 to $332.00. They now have a “buy” rating on the stock.

Insiders Place Their Bets

In other Ligand Pharmaceuticals news, Director Jason Haas sold 6,461 shares of the firm’s stock in a transaction that occurred on Friday, June 12th. The stock was sold at an average price of $255.58, for a total value of $1,651,302.38. Following the sale, the director owned 4,981 shares of the company’s stock, valued at $1,273,043.98. This trade represents a 56.47% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Stephen L. Sabba sold 2,145 shares of the business’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $254.00, for a total transaction of $544,830.00. Following the transaction, the director directly owned 33,629 shares in the company, valued at $8,541,766. This trade represents a 6.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 35,698 shares of company stock valued at $9,019,252 in the last three months. Company insiders own 5.60% of the company’s stock.

Ligand Pharmaceuticals, Inc is a biopharmaceutical company that acquires, develops and out-licenses proprietary technologies designed to help pharmaceutical and biotechnology companies discover and develop novel medicines. Operating primarily through its research services and royalty-generating businesses, Ligand focuses on building a diversified portfolio of technology platforms and partnering with industry leaders to advance therapeutic candidates across multiple disease areas.

The company’s product offerings center around several core platforms.